{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-011467","form_type":"8-K","ticker":"FENC","cik":"0001211583","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2022-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.155822+00:00","generated_at":"2026-06-24T06:20:03.486183+00:00","sec_items":["1.01","2.03","3.02","8.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Fennec secures up to $45M from Petrichor; $5M now, $20M on FDA approval of PEDMARK","bullets":["Petrichor invests $5M in convertible notes at $8.11/share; $20M additional due upon FDA approval of PEDMARK by Sep 30, 2022.","Notes: US Prime +4.5% interest, 3.5% PIK for 24 months, maturity Aug 1, 2027; company will repay Bridge Bank debt.","Potential $20M more available before Dec 31, 2023; funds support PEDMARK launch for cisplatin-induced ototoxicity.","PEDMARK PDUFA target action date is Sep 23, 2022; first FDA-approved therapy to reduce ototoxicity risk."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-011467","json":"https://secwatch.observer/filing/0001558370-22-011467.json","markdown":"https://secwatch.observer/filing/0001558370-22-011467.md","text":"https://secwatch.observer/filing/0001558370-22-011467.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1211583/000155837022011467/0001558370-22-011467-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1211583/000155837022011467/fencf-20220801x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T06:20:03.486183+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}